Definition and epidemiology
Juvenile spondyloarthritis (JSpA) is an umbrella term for a group of HLA-B27-associated inflammatory arthritides beginning before age 16, dominated early by peripheral arthritis and enthesitis rather than the inflammatory back pain that characterises adult disease. In the ILAR juvenile idiopathic arthritis (JIA) scheme its closest counterpart is enthesitis-related arthritis (ERA), alongside juvenile-onset ankylosing spondylitis, reactive arthritis, and the arthritis of inflammatory bowel disease. It typically affects older boys (>6 years), is strongly linked to HLA-B27, and carries a meaningful risk of progression to axial (sacroiliac) disease over the following years.
Clinical features
- Peripheral arthritis — asymmetric, predominantly lower-limb, large-joint oligoarthritis (hips, knees, ankles).
- Enthesitis — inflammation at tendon/ligament insertions; classic sites are the Achilles insertion, plantar fascia, and around the patella. A defining and often presenting feature.
- Axial involvement — inflammatory back/buttock pain and sacroiliitis tend to develop later; alternating buttock pain is suggestive. Axial disease emerges in a substantial proportion within ~5 years.
- Extra-articular — acute symptomatic anterior uveitis (red, painful eye — distinct from the chronic asymptomatic uveitis of oligoarticular JIA), tarsitis/dactylitis, and association with psoriasis or IBD.
Diagnosis
JSpA is a clinical diagnosis supported by classification frameworks. The ASAS criteria are entered via the dominant presentation: the peripheral SpA arm (arthritis, enthesitis, or dactylitis plus SpA features such as HLA-B27, uveitis, sacroiliitis on imaging, psoriasis, IBD, preceding infection, or a family history) tends to perform better in children, since most present peripherally; the axial SpA arm (sacroiliitis on imaging or HLA-B27 plus SpA features, with chronic back pain ≥3 months and onset <45 years) captures those with established back disease. The overlapping ILAR ERA criteria are also widely used. Investigations: HLA-B27, inflammatory markers, and imaging — MRI of the sacroiliac joints (active inflammation) is more sensitive than radiography in children. Note ASAS criteria were derived in adults and are not formally validated in pediatrics.
See the full criteria: ASAS Criteria for Spondyloarthritis (SpA)
Red flags
- Acute painful red eye — symptomatic anterior uveitis (urgent ophthalmology)
- Progressive hip arthritis with loss of range — a poor prognostic marker
- Persistent inflammatory back/buttock pain with night waking and morning stiffness — evolving axial disease
- GI symptoms, weight loss, or anaemia — evaluate for inflammatory bowel disease
- Fever, severe systemic illness, or bone pain — exclude infection and malignancy
Management overview
Treatment follows a treat-to-target, step-up strategy (drug classes/strategy only):
- First line — NSAIDs for pain, enthesitis, and axial symptoms, combined with physiotherapy to preserve range and posture.
- Local therapy — intra-articular corticosteroid injections for active peripheral joints.
- Peripheral disease inadequately controlled — a conventional synthetic DMARD (e.g. methotrexate or sulfasalazine), which help peripheral arthritis but not axial disease.
- Axial disease or refractory peripheral/entheseal disease — escalate to biologic DMARDs, principally TNF inhibitors (effective for axial, peripheral, enthesitis, and uveitis), with IL-17 inhibitors as an alternative.
- Manage uveitis jointly with ophthalmology; address bowel disease where present.
Care is multidisciplinary (pediatric rheumatology, ophthalmology, physiotherapy) with longitudinal monitoring for axial progression and uveitis.
References
- Rudwaleit M, et al. ASAS classification criteria for peripheral SpA / SpA in general. Ann Rheum Dis. 2011;70:25-31.
- Rudwaleit M, et al. ASAS classification criteria for axial SpA. Ann Rheum Dis. 2009;68:777-783.
- Petty RE, et al. ILAR classification of JIA, Edmonton 2001. J Rheumatol. 2004;31:390-392.
Decision support for qualified clinicians only — verify against current primary guidelines and your clinical judgement.